U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06986369) titled 'Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases' on March 07, 2024.
Brief Summary: The specific mechanistic benefit of rivaroxaban versus other FXa inhibitors on atherothrombotic events remain unclear. Therefore plan to initiate a prospective, randomized study to investigate the effect of rivaroxaban and aspirin versus aspirin alone on changes of number circulating endothelial cells and endothelial function, and alteration in systemic inflammation, platelet and coagulation activation in patients with stable atherosclerotic vascular diseases.
The working hypothesis of this trial is tha...